Stockscreener 앱 받기
1.98
6.60%
-0.14
전일 마감가:
$2.12
열려 있는:
$2.12
하루 거래량:
226.55K
Relative Volume:
0.34
시가총액:
$61.34M
수익:
-
순이익/손실:
$-21.24M
주가수익비율:
-2.3631
EPS:
-0.8379
순현금흐름:
$-22.47M
1주 성능:
+4.21%
1개월 성능:
-1.00%
6개월 성능:
-55.90%
1년 성능:
-83.00%
1일 변동 폭
$1.955
$2.12
1주일 범위
$1.91
$2.28
52주 변동 폭
$1.14
$12.11
Skye Bioscience Inc Stock (SKYE) Company Profile
명칭
Skye Bioscience Inc
전화
(858) 410-0266
주소
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
SKYE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.43 | 372.90M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
11.50 | 190.93M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.76 | 131.34M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1601 | 350.74M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
MOBBW
Mobilicom Limited Warrants
|
0.4197 | 636.80M | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-28 | 개시 | William Blair | Outperform |
| 2024-09-30 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-10 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-09 | 개시 | Craig Hallum | Buy |
| 2024-05-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-04-12 | 개시 | Oppenheimer | Outperform |
모두보기
Skye Bioscience Inc 주식(SKYE)의 최신 뉴스
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Sold by Northern Trust Corp - Defense World
Skye Bioscience (NASDAQ:SKYE) Stock Price Up 24%Still a Buy? - MarketBeat
Skye Bioscience (NASDAQ:SKYE) Trading Up 24% – Should You Buy? - Defense World
Skye Bioscience (NASDAQ:SKYE) Trading Up 24% – Here’s What Happened - Defense World
Skye Bioscience’s SWOT analysis: obesity drug stock poised for pivotal data - Investing.com Nigeria
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Sold by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $923,000 Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies - Zacks Investment Research
Arecor CEO on Skye Bioscience partnership and the value of collaborations - Proactive financial news
Skye Bioscience to Participate in Upcoming Investment Conferences - GlobeNewswire
Skye Bioscience to Participate in Upcoming Investment Conferences - GlobeNewswire Inc.
Skye Bioscience (NASDAQ:SKYE) Earns Outperform Rating from William Blair - Defense World
Skye Bioscience’s (SKYE) Outperform Rating Reiterated at William Blair - Defense World
Ensign Peak Advisors Inc Has $2.17 Million Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - MarketBeat
Protagenic and Phytanix merger prompts a stock surge - BioWorld MedTech
Skye Bioscience Establishes Partnership with Arecor Therapeutics - GuruFocus
Pre-market Movers: HCTI, PTIX, BCLI, AFMD... - RTTNews
Arecor shares jump 10% on obesity drug partnership with Skye Bioscience - Proactive financial news
Arecor partners with Skye Bioscience to improve formulation of obesity drug - Proactive financial news
Skye Bioscience Partners with Arecor Therapeutics to Enhance Nimacimab Formulation for Obesity Treatment - Nasdaq
Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab - The Manila Times
Skye Bioscience Establishes Partnership with Arecor - GlobeNewswire
New Obesity Drug Breakthrough: Skye Bioscience's Once-Weekly Treatment Gets Powerful Upgrade - Stock Titan
Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Skye Bioscience (NASDAQ:SKYE) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of “Buy” from Analysts - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives $16.60 Consensus PT from Analysts - Defense World
Brokerages Set Skye Bioscience, Inc. (NASDAQ:SKYE) Target Price at $16.60 - Defense World
Skye Bioscience Awards 100,000 Share Options at $1.82 with 4-Year Vesting Terms - Stock Titan
Skye Bioscience (SKYE) Reveals Key Findings on CB1 Inhibitors an - GuruFocus
Skye Bioscience Clinical Model Demonstrating Necessity of - GlobeNewswire
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity - Stock Titan
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Bought by Barclays PLC - Defense World
Barclays PLC Has $198,000 Stock Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience (SKYE) Receives Adjusted Price Target from Oppen - GuruFocus
Oppenheimer cuts Skye Bioscience price target to $17 By Investing.com - Investing.com South Africa
Oppenheimer cuts Skye Bioscience price target to $17 - Investing.com
Braidwell LP Invests $2.34 Million in Skye Bioscience, Inc. (NASDAQ:SKYE) - MarketBeat
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Skye Bioscience, Inc. (SKYE) - ACCESS Newswire
Earnings call transcript: Skye Bioscience Reports Q1 2025 Financials Amid R&D Expansion - Investing.com Nigeria
Skye Bioscience, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SKYE) - Seeking Alpha
Skye Bioscience Inc (SKYE) Q1 2025 Earnings Call Highlights: Pro - GuruFocus
Skye Bioscience Inc (SKYE) Q1 2025 Earnings Call Highlights: Promising Trial Progress and Financial Stability Amid Regulatory Challenges - GuruFocus
Skye Bioscience Inc (SKYE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Skye Bioscience Inc 주식 (SKYE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Diep Tuan Tu | Chief Development Officer |
Nov 15 '24 |
Sale |
5.55 |
85 |
472 |
101,748 |
| ARSENAULT KAITLYN | Chief Financial Officer |
Nov 18 '24 |
Sale |
4.99 |
43,206 |
215,598 |
166,342 |
| ARSENAULT KAITLYN | Chief Financial Officer |
Nov 15 '24 |
Sale |
5.55 |
190 |
1,054 |
209,548 |
| DHILLON PUNIT | Chief Executive Officer |
Nov 18 '24 |
Sale |
4.99 |
82,546 |
411,905 |
329,823 |
| DHILLON PUNIT | Chief Executive Officer |
Nov 15 '24 |
Sale |
5.55 |
364 |
2,020 |
412,369 |
| Grayson Paul A. | Director |
Nov 18 '24 |
Sale |
4.99 |
86,244 |
430,358 |
259,701 |
| Grayson Paul A. | Director |
Nov 15 '24 |
Sale |
5.55 |
307 |
1,704 |
345,945 |
1.89%
3.74%
자본화:
|
볼륨(24시간):